Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)

被引：0
|
作者：
Herbst, R. S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Sun, Y. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Korfee, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Germonpre, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Saijo, N. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Zhou, C. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Wang, J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Langmuir, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Kennedy, S. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Johnson, B. E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Canc Hosp Beijing, Beijing, Peoples R China
[3] Univ Duisburg Essen, W German Tumor Ctr, Essen, Germany
[4] Univ Antwerp Hosp, Edegem, Belgium
[5] East Hosp, Natl Canc Ctr, Chiba, Japan
[6] Tongji Univ, Shanghai 200092, Peoples R China
[7] Beijing Inst Canc Res, Beijing, Peoples R China
[8] AstraZeneca, Wilmington, DE USA
[9] AstraZeneca, Macclesfield, Cheshire, England
[10] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CRA8003
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC)
    Leighl, N
    Laurie, S
    Knox, J
    Ellis, P
    Shepherd, F
    Burkes, R
    Pond, G
    Zwiebel, J
    Moore, M
    [J]. LUNG CANCER, 2005, 49 : S256 - S256
  • [32] Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC
    Johnson, B. E.
    Ryan, A. J.
    Heymach, J.
    Stephens, C.
    Kennedy, S. J.
    Langmuir, P. B.
    Herbst, R. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Exposure-response relationship for ramucirumab (RAM) from the randomized, double-blind, phase III REVEL trial (docetaxel [DOC] vs DOC plus RAM) in second-line treatment of metastatic non-small cell lung cancer (NSCLC).
    Smit, Egbert F.
    Perol, Maurice
    Reck, Martin
    Cappuzzo, Federico
    Bidoli, Paolo
    Cohen, Roger B.
    Gao, Ling
    Ernest, C. Steven
    Lee, Pablo
    Zimmermann, Annamaria
    Ferry, David
    Treat, Joseph
    Melemed, Allen S.
    Garon, Edward B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?
    Cortinovis, Diego
    Bidoli, Paolo
    Cullura, Daniela
    Lorusso, Vito
    Ardizzoia, Antonio
    Amoroso, Vito
    Bandera, Mauro
    Aitini, Enrico
    Fusi, Alberto
    Zilembo, Nicoletta
    Radula, Daniela
    Bajetta, Emilio
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 405 - 411
  • [35] Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
    Pesek, M
    Holá, V
    [J]. LUNG CANCER: CURRENT TOPICS, 2001, : 155 - 160
  • [36] A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer
    Athanasios G Pallis
    Sophia Agelaki
    Athina Agelidou
    Ioannis Varthalitis
    Kostas Syrigos
    Nikolaos Kentepozidis
    Georgia Pavlakou
    Athanasios Kotsakis
    Emmanouel Kontopodis
    Vassilis Georgoulias
    [J]. BMC Cancer, 10
  • [37] Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with weekly versus three-weekly docetaxel: Results of a randomized phase III study.
    Schuette, W
    Nagel, S
    Serke, M
    Lautenschlaeger, C
    Hans, K
    Lorenz, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 625S - 625S
  • [38] A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer
    Pallis, Athanasios G.
    Agelaki, Sophia
    Agelidou, Athina
    Varthalitis, Ioannis
    Syrigos, Kostas
    Kentepozidis, Nikolaos
    Pavlakou, Georgia
    Kotsakis, Athanasios
    Kontopodis, Emmanouel
    Georgoulias, Vassilis
    [J]. BMC CANCER, 2010, 10
  • [39] Cisplatin plus docetaxel as second-line treatment in metastatic non-small-cell lung cancer (NSCLC)
    Doria, Simona
    Prochilo, Tiziana
    Cafferata, Mara Argenide
    Tiseo, Marcello
    Ardizzoni, Andrea
    Baldini, Editta
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 28 - 29
  • [40] A phase II study of docetaxel (D) and gemcitabine (G) as second-line treatment in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Agelaki, S
    Papadakis, E
    Tsiafaki, X
    Rapti, A
    Toubis, M
    Bania, E
    Kalbakis, K
    Kouroussis, C
    Androulakis, N
    Georgoulias, V
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S256 - S256
12345